Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lynparza in HER2-negative breast cancer
NCT05033756Phase 2Active, not recruiting
- Sponsor
- Institut Frauengesundheit
- Start
- Jul 2022
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in breast cancer, sponsored by Institut Frauengesundheit. Started Jul 2022; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05033756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033756.